HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
Want to see GB:HEMO full AI Analyst Report?
HEMO Stock Chart & Stats
568.00 p
-12.50 p(-3.23%)
At close: 4:00 PM EST
568.00 p
-12.50 p(-3.23%)
Day’s Range― - ―
52-Week Range124.00 p - 1,800.00 p
Previous CloseN/A
Volume114.00
Average Volume (3M)113.41K
Market Cap
£45.83M
Enterprise Value46.49M
Total Cash (Recent Filing)£1.59M
Total Debt (Recent Filing)£2.00M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding6,799,961
10 Day Avg. Volume30,447
30 Day Avg. Volume113,406
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt ReductionA multi-year reduction in total debt meaningfully lowers financing pressure for a loss-making biotech. Reduced debt cuts future interest/service needs and modestly extends runway, improving the company's ability to fund R&D or negotiate partnerships without immediate refinancing risk.
Improving Cash BurnA demonstrable reduction in annual operating cash outflows shows management has begun narrowing structural cash burn. Sustained improvement preserves cash reserves longer, lowers near-term capital needs, and increases probability of reaching clinical or licensing milestones before a dilutive raise.
Focused Clinical NicheConcentrated R&D in hematology/oncology and stem cell transplantation targets areas with high unmet need and potential premium pricing or partnership interest. A platform-oriented approach in a specialized therapeutic area supports durable competitive positioning and licensing or collaboration opportunities.
Bears Say
Pre-revenue ProfileAbsence of any revenue forces reliance on external capital and milestone/licensing events to sustain operations. For a development-stage biotech this raises long-term dilution risk, restricts reinvestment capacity, and creates uncertainty around the timing and certainty of commercialization.
Widening Net LossesAccelerating annual losses materially increase the funding runway required to reach clinical inflection points. Growing deficits deplete equity cushions, amplify the need for capital raises, and raise execution risk if milestones or partnerships do not materialize on schedule.
Elevated Leverage & Shrinking EquityA leveraged balance sheet with a sharply reduced equity base leaves limited shock absorption for a loss-making company. High debt relative to equity constrains financial flexibility, increases refinancing or covenant risk, and heightens the likelihood of dilutive financing under adverse funding conditions.
HemoGenyx Pharmaceuticals Plc News
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 124.00 p and its highest was 1800.00 p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is £45.83M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 24, 2026 which is in 127 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 30, 2026. The company reported -0.787 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.787 p.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,799,961 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -0.787 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.23%
12-Months-Change
Fundamentals
Return on Equity
-3931.14%
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Technical Analysis
ImmuPharma
―
Open Orphan Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---